Leucine Rich Bio Launches in Dubai

Leucine Rich Bio, South Asia’s pioneering microbiome company, has launched Leucine Rich Bio Middle East FZCO in Dubai, targeting the rapidly growing microbiome wellness market in the GCC and MENA region.

Leveraging over a decade of microbiome expertise and one of Asia’s largest microbiomic data repositories, the company introduces its flagship solutions: BugSpeaks, a microbiome diagnostic test, and Rychbiome, personalized wellness formulations. The Dubai hub will foster partnerships with healthcare providers, research institutions, and wellness ecosystems to deliver precision wellness and preventive care solutions tailored to regional health needs.

The global microbiome diagnostics market, valued at USD 145-150 million in 2023, is projected to reach USD 300 million by 2028, growing at a CAGR of 15.5%. In the Middle East & Africa, the microbiome analysis market, worth USD 41.5 million in 2024, is expected to hit USD 57.7 million by 2030 (CAGR 6%).

Also Read: Overcoming Patient Management Challenges with Healthcare CRM

The UAE’s microbiome analysis market, valued at USD 7.6 million in 2024, is forecast to reach USD 10.6 million by 2030 (CAGR 6.2%). The region’s microbiome therapeutics segment is anticipated to grow at a CAGR of 16.6% through 2030, reaching USD 11 million, signaling strong demand for personalized health solutions.

Kumar Sankaran, CEO, stated, “Dubai’s emergence as a healthcare innovation hub makes it the perfect base to deliver advanced microbiome testing and co-develop region-specific solutions with local partners.”

Hidayath Shariff, Managing Partner – Dubai, added, “The UAE’s commitment to healthcare innovation aligns with our mission to integrate microbiome science into everyday wellness.”

Also Read: Value-Based Healthcare: A Path to Better Decision-Making and Health Outcomes

Key Offerings:

• BugSpeaks: South Asia’s first microbiome test, providing insights into immunity, metabolism, and mental health through DNA sequencing and proprietary analytics. Certified with ISO 9001, ISO 17025, NABH, and NABL, it includes gut, skin, vaginal, and oral microbiome profiling.
• Research Partnerships: Collaborative projects to drive therapeutic innovations tailored to the regional microbiome landscape.